TY - JOUR
T1 - Agonist induced-phosphorylation of Gα11 protein reduces coupling to 5-HT2A receptors
AU - Shi, Ju
AU - Damjanoska, Katerina J.
AU - Singh, Rakesh K.
AU - Carrasco, Gonzalo A.
AU - Garcia, Francisca
AU - Grippo, Angela J.
AU - Landry, Michelle
AU - Sullivan, Nicole R.
AU - Battaglia, George
AU - Muma, Nancy A.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2007/10
Y1 - 2007/10
N2 - We previously demonstrated that 24-h treatment with (-)-1-(2,5-dimethoxy-4- iodophenyl)-2-aminopropane HCl (DOI) causes phosphorylation of G α11 protein at serine 154 and that this phosphorylation causes desensitization of serotonin (5-HT) 2A receptor signaling in A1A1v cells (Shi et al., 2007). We now report that treatment of A1A1v cells with DOI for 24 h produces a greater reduction in the Bmax of [125I] (±)-DOI-labeled high-affinity binding sites (46%) than the reduction of [3H]ketanserin binding sites (25%). Although the KD values are not altered, there is a smaller amount of GTPγS [guanosine 5′-3-O-(thio)-triphosphate]-sensitive [125I](±)-DOI binding in DOI-treated cells. These results suggest that DOI treatment causes downregulation of 5-HT2A receptors and reductions in G protein-coupled 5-HT2A receptors. In contrast, in cells transfected with the phosphorylation state mimic Gα11S154D, GTPγS-sensitive [125I](±)-DOI binding was decreased by 48%; however, there was no significant difference in the KD and Bmax values of [125I](±)-DOI-labeled receptors. The receptor binding experiments suggest that phosphorylation of G α11 on serine 154 reduces coupling of 5-HT2A receptors, whereas DOI causes down-regulation of 5-HT2A receptors in addition to the phosphorylation-induced uncoupling of Gα11 to 5-HT2A receptors. To determine whether DOI increases phosphorylation of Gαq/11 protein in vivo, rats were treated with 1 mg/kg/day DOI or saline for 1 to 7 days. Seven days of DOI treatment significantly decreased phospholipase C activity stimulated by an Emax concentration of 5-HT by 40% and increased phosphorylation of G αq/11 proteins by 51% in the frontal cortex. These data suggest that DOI causes phosphorylation of Gαq/11 in vivo and could thereby contribute to the desensitization of 5-HT2A receptors.
AB - We previously demonstrated that 24-h treatment with (-)-1-(2,5-dimethoxy-4- iodophenyl)-2-aminopropane HCl (DOI) causes phosphorylation of G α11 protein at serine 154 and that this phosphorylation causes desensitization of serotonin (5-HT) 2A receptor signaling in A1A1v cells (Shi et al., 2007). We now report that treatment of A1A1v cells with DOI for 24 h produces a greater reduction in the Bmax of [125I] (±)-DOI-labeled high-affinity binding sites (46%) than the reduction of [3H]ketanserin binding sites (25%). Although the KD values are not altered, there is a smaller amount of GTPγS [guanosine 5′-3-O-(thio)-triphosphate]-sensitive [125I](±)-DOI binding in DOI-treated cells. These results suggest that DOI treatment causes downregulation of 5-HT2A receptors and reductions in G protein-coupled 5-HT2A receptors. In contrast, in cells transfected with the phosphorylation state mimic Gα11S154D, GTPγS-sensitive [125I](±)-DOI binding was decreased by 48%; however, there was no significant difference in the KD and Bmax values of [125I](±)-DOI-labeled receptors. The receptor binding experiments suggest that phosphorylation of G α11 on serine 154 reduces coupling of 5-HT2A receptors, whereas DOI causes down-regulation of 5-HT2A receptors in addition to the phosphorylation-induced uncoupling of Gα11 to 5-HT2A receptors. To determine whether DOI increases phosphorylation of Gαq/11 protein in vivo, rats were treated with 1 mg/kg/day DOI or saline for 1 to 7 days. Seven days of DOI treatment significantly decreased phospholipase C activity stimulated by an Emax concentration of 5-HT by 40% and increased phosphorylation of G αq/11 proteins by 51% in the frontal cortex. These data suggest that DOI causes phosphorylation of Gαq/11 in vivo and could thereby contribute to the desensitization of 5-HT2A receptors.
UR - http://www.scopus.com/inward/record.url?scp=34548820222&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548820222&partnerID=8YFLogxK
U2 - 10.1124/jpet.107.122317
DO - 10.1124/jpet.107.122317
M3 - Article
C2 - 17646429
AN - SCOPUS:34548820222
SN - 0022-3565
VL - 323
SP - 248
EP - 256
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 1
ER -